THE TGA has posted new Australian Public Assessment Reports (AusPARs) covering CSL Behring's IV haemophilia treatment Idelvion (albutrepenonacog alpha), Takeda's Adcetris (brentuximab vedotin) for Hodgkin lymphoma and GSK's Volibris (ambrisentan) for treatment of COPD - see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Oct 17